Network connectivity and local transcriptomic vulnerability underpin cortical atrophy progression in Parkinson's disease.

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 acknowledgements ppmi---a public-private partnership---is funded by the michael j fox foundation for parkinson's research and funding partners including abbvie avid biogen bristol-myers squibb covance ge healthcare genentech glaxosmithkline lilly lundbeck merck meso scale discovery pfizer piramal sanofi genzyme servier teva and ucb."

"Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

"PPMI---a public-private partnership---is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Sanofi Genzyme, Servier, Teva, and UCB. This research was supported by grants from the Michael J. Fox Foundation for Parkinson’s Research, the W. Garfield Weston Foundation, the Alzheimer’s Association, and the Canadian Institutes of Health Research to AD. AV acknowledges support from Frontiers de Rechèrche du Québec – Santé (FRQS). SR received a scholarship from the Canadian Institutes of Health Research (CIHR)."